


RESEARCH

Open Access



Association between circulating alpha-1 antitrypsin polymers and lung and liver disease

Alexa Núñez^{1,2†}, Irene Belmonte^{1†}, Elena Miranda³, Miriam Barrecheguren¹, Georgina Farago¹, Eduardo Loeb⁴, Mònica Pons⁵, Francisco Rodríguez-Frías^{2,6,7,8}, Pablo Gabriel-Medina⁶, Esther Rodríguez¹, Joan Genescà^{2,5,7}, Marc Miravittles^{1,2,9*}  and Cristina Esquinas^{1,2}

Abstract

Background: Alpha-1 antitrypsin deficiency (AATD) is considered one of the most common genetic diseases and is characterised by the misfolding and polymerisation of the alpha-1 antitrypsin (AAT) protein within hepatocytes. The relevance of circulating polymers (CP) of AAT in the pathogenesis of lung and liver disease is not completely understood. Therefore, the main objective of our study was to determine whether there is an association between the levels of CP of AAT and the severity of lung and liver disease.

Method: This was a cross-sectional study in patients with different phenotypes of AATD and controls. To quantify CP, a sandwich ELISA was performed using the 2C1 monoclonal antibody against AAT polymers. Sociodemographic data, clinical characteristics, and liver and lung parameters were collected.

Results: A cohort of 70 patients was recruited: 32 Pi*ZZ (11 on augmentation therapy); 29 Z-heterozygous; 9 with other genotypes. CP were compared with a control group of 47 individuals (35 Pi*MM and 12 Pi*MS). ZZ patients had the highest concentrations of CP ($p < 0.001$) followed by Z heterozygous. The control group and patients with Pi*SS and Pi*SI had the lowest CP concentrations. Pi*ZZ also had higher levels of liver stiffness measurements (LSM) than the remaining AATD patients. Among patients with one or two Z alleles, two patients with lung and liver impairment showed the highest concentrations of CP (47.5 $\mu\text{g}/\text{mL}$), followed by those with only liver abnormality ($n = 6$, CP = 34 $\mu\text{g}/\text{mL}$), only lung ($n = 18$, CP = 26.5 $\mu\text{g}/\text{mL}$) and no abnormalities ($n = 23$, CP = 14.3 $\mu\text{g}/\text{mL}$). Differences were highly significant ($p = 0.004$).

Conclusions: Non-augmented Pi*ZZ and Z-patients with impaired lung function and increased liver stiffness presented higher levels of CP than other clinical phenotypes. Therefore, CP may help to identify patients more at risk of developing lung and liver disease and may provide some insight into the mechanisms of disease.

Keywords: Alpha-1 antitrypsin deficiency, Circulating polymers, Emphysema, Liver disease

Background

Alpha-1 antitrypsin deficiency (AATD) is considered one of the most common genetic disorders in adults [1], with a prevalence of 1 in 2000 to 3000 live births in Europe [2]. AATD is characterised by low circulating levels of the alpha-1 antitrypsin (AAT) protein caused by specific mutations in the *SERPINA1* gene resulting in a misfolded protein and intracellular liver polymerization. *SERPINA1* is highly polymorphic with at least 120 mutations having

*Correspondence: marcmm@separ.es

[†]Alexa Núñez and Irene Belmonte contributed equally and should be considered first authors

¹ Pneumology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, P.Vall d'Hebron 119-129, 08035 Barcelona, Spain
Full list of author information is available at the end of the article



been described, and of these, 60 are deficient variants [3, 4]. The normal allele present in 95% of healthy individuals is defined as the M allele, and the most common deficient variants are S and Z [5, 6]. The alleles of *SERPINA1* are codominant, therefore, individuals heterozygous and homozygous for the Z allele have AAT plasma concentrations of 50% and 10 to 15% of normal, respectively.

In normal conditions, the protein is mainly synthesised and secreted by hepatocytes and its main function is to protect lung tissue from damage caused by proteolytic enzymes such as neutrophil elastase. In the presence of the Z allele, most of the AAT synthesised polymerises and accumulates in the lumen of the endoplasmic reticulum (ER) of liver cells as inclusion bodies. These inclusions are associated with neonatal hepatitis, cirrhosis and hepatocellular carcinoma [7]. In addition, lower concentrations of circulating AAT predispose to early onset panlobular emphysema in individuals with smoking history [8–10].

Polymers of AAT have also been identified in the bronchoalveolar lavage fluid and alveolar walls of carriers of the Z allele [11]. In a study by Alam et al. [12], it was observed that cigarette smoking accelerated polymerisation of AAT in patients homozygous for the Z allele, leading to a greater depletion of the protection against neutrophil elastase in the lung. Later, other authors found that these circulating polymers (CP) of AAT were present in serum samples of AATD Pi*ZZ and mixed phenotypes patients, probably due to secretion to the circulation from liver cells [13, 14].

However, little is known about the role of CP of AAT in the pathogenesis of disease in patients with AATD. Therefore, the aim of our study was to determine CP concentrations in individuals with different genotypes of AAT and to investigate the association between CP and the severity of lung and liver disease in patients with AATD homozygous and heterozygous for the Z allele.

Methods

This was a cross-sectional study performed in the Vall d'Hebron Hospital Campus (Barcelona, Spain), which is a reference centre for AATD [15]. Patients with moderate and severe deficiency (genotypes Pi*SS, MZ, SZ, ZZ and rare variants) were consecutively included from the AATD outpatient clinic of the Pneumology Department between January and December 2019. A control group of adults, older than 18 years with Pi*MM and Pi*MS genotypes were also consecutively recruited during the same period among those attending routine medical check-ups in the Preventive Medicine outpatient clinic in our centre.

The study was carried out according to the principles of the Declaration of Helsinki and the prevailing norms for

performing investigation in humans. Data confidentiality was ensured according to the Law of Data Protection 2016/679. The study was approved by the Ethical Committee and Clinical Investigation of the Vall d'Hebron University Hospital (Barcelona, Spain) number PR (AG) 156/2016, and all the participants provided written informed consent.

Variables

Sociodemographic data and clinical characteristics were collected from all patients. Comorbidities were registered according to the Charlson comorbidity index [16]. Patients performed spirometry and values for forced expiratory volume in the 1st second (FEV₁), forced vital capacity (FVC) and the FEV₁/FVC ratio were registered. Chronic obstructive pulmonary disease (COPD) was diagnosed when the post-bronchodilator FEV₁/FVC ratio was below 0.7.

Liver stiffness measurement (LSM) was performed using transient elastography (Fibroscan 502 Touch, Echosens, Paris, France) in a fasting state according to the usual standard procedure [17]. Quality criteria were at least 10 valid measurements and an interquartile to median ratio $\leq 30\%$. Only valid assessments were considered for the analysis. Data were expressed in kilopascals (kPa). Normal LSM values vary between 4–6 kPa. LSM ≥ 6 kPa were considered abnormal and suggestive of liver disease/mild fibrosis.

Laboratory testing

Biochemical tests included determination of liver enzymes: aspartate-aminotransferase (AST), alanine-aminotransferase (ALT), gamma-glutamyl transferase and alkaline phosphatase. In addition, two fibrosis biomarkers were assessed: the fibrosis-4 (FIB-4) score and the enhanced liver fibrosis (ELF) test. The FIB-4 score was calculated as age (years) \times AST [IU/L]/(platelet count [10^9 /L] \times $\sqrt{\text{ALT}}$ [IU/L]). The ELF test (Siemens Healthcare Diagnostics, Vienna, Austria) consists of three components: type III procollagen peptide, hyaluronic acid and tissue inhibitor of metalloproteinase-1 and is a marker of liver fibrosis [18]. In addition, fibrinogen and C-reactive protein (CRP) were determined as markers of systemic inflammation.

AAT blood levels and genotyping

Quantitative measurement of AAT levels was determined by immune nephelometry and genotyping was performed using real-time polymerase chain reaction or sequencing the entire encoding region of the *SERPINA1* gene as previously described [15].

Circulating polymers of AAT

To quantify CP, a sandwich ELISA with plasma samples was performed using the 2C1 monoclonal antibody (mAb) against AAT polymers [19]. Plates were coated overnight at room temperature with 50 µL/well of purified 2C1 mAb at 2 µg/mL. The next day, the plates were washed and incubated with 300 µL/well of blocking solution for 1 h. Standards and samples were diluted in blocking buffer, added to the plate and incubated for 2 h at room temperature. Bound polymers were detected with anti-total AAT 3C11 mAb labelled with horseradish peroxidase and incubated for 75 min, and its activity was subsequently measured in a plate reader at 450 nm using a 3,3',5,5'-tetramethylbenzidine (TMB) substrate solution. CP (µg/mL) concentrations were determined by interpolation of absorbance values on the standard curve [20]. Monoclonal antibody 2C1 recognizes the pathological polymers formed by AAT, however, in samples with elevated AAT concentrations and the absence of polymers, a minimal amount of monomeric AAT binds to mAb 2C1 with low affinity, showing a weak background signal. In order to reduce this noise, the proportion of polymers versus the total levels of AAT (%) was determined in all samples together with total polymer concentrations (µg/mL).

Statistical analysis

Qualitative variables were described with absolute frequencies and percentages. The description of quantitative variables was performed using the mean, standard deviation (SD), median and quartiles. The Kolmogorov–Smirnov test was used to assess the normality of distributions.

The sociodemographic, clinical characteristics and CP levels (µg/mL and %) were compared according to the genotypes. In the case of quantitative variables, ANOVA tests were carried out with Bonferroni correction for multiple comparisons. The Chi-squared test (Fisher test for frequencies < 5) was used for the comparison of categorical variables. Linear relationships between clinical variables and levels of CP were also analysed using the Pearson correlation coefficient.

For all the tests, p-values < 0.05 were considered statistically significant. The statistical package R Studio (V2.5.1) was used for the analyses.

Results

Characteristics of participants

A total of 70 patients with different AAT genotypes were included. Among them, 32 (46%) were homozygous Pi*ZZ, of whom 11 were on augmentation therapy; 29 (41%) were heterozygous for the Z allele (13 Pi*MZ,

13 Pi*SZ, 1 Pi*MmaltonZ, 1 Pi*PLowelZ, 1 Pi*FZ); 4 (6%) carriers of the S allele (3 Pi*SS, 1 Pi*SI); and 5 (7%) rare variants (1 Pi*MMmattawa, 2 Pi*MMmalton, 1 Pi*SMmalton and 1 Pi*MMvall d'Hebron) (Table 1). The control group consisted of 47 individuals with a mean age of 46 years (SD = 14.1) and 17 (36.2%) were male; 35 had a normal genotype Pi*MM and 12 had a Pi*MS genotype.

Sociodemographic and clinical characteristics of patients according to the AATD genotype

Patients were divided into three groups according to their AATD genotype: (1) homozygous Pi*ZZ, (2) heterozygous for the Z allele, (3) others: Pi*SS, Pi*SI, Pi*MMmattawa, Pi*MMmalton, Pi*SMmalton and Pi*MMvall d'Hebron.

No differences were observed between groups in terms of age, body mass index or sex distribution (Table 2).

Homozygous Pi*ZZ patients had a lower FVC% (p = 0.014), a lower FEV₁% (p = 0.07) and higher percentage of COPD (p = 0.008) than the other genotypes. Moreover, Pi*ZZ individuals showed higher LSM (p = 0.018) and ELF levels (p = 0.004) compared to the remaining patients.

Regarding laboratory findings, as expected, Pi*ZZ patients presented lower AAT levels (p < 0.001). No significant differences were observed for leukocytes, platelets, liver enzymes, CRP, FIB-4 or fibrinogen concentrations among groups (Table 2).

Circulating polymer concentrations in the different AATD genotypes

As a group, the Pi*ZZ patients presented higher concentrations of CP than heterozygous patients and those with other genotypes (Table 2).

Table 1 Description of AAT variants identified in the study population

| Variant | Codon change | Classification | Deficiency |
|------------------------|-------------------------------------|----------------|--|
| M | – | Normal | Not deficient |
| Z | Glu342Lys | Deficient | Severe |
| S | Glu264Val | Deficient | Moderate |
| F | Arg223Cys | Deficient | Not deficient Reduced inhibitory activity |
| I | Arg39Cys | Deficient | Moderate |
| Mmalton | Phe52del (M ₂) | Deficient | Severe |
| Mvall d'hebron | Pro369Ser | Deficient | Moderate |
| Plowell | Asp256Val (M ₃) | Deficient | Severe |
| Q ₀ mattawa | Leu353Phefs*24 (M _{1val}) | Null | Severe |

AAT alpha-1 antitrypsin, AATD alpha-1 antitrypsin deficiency

Table 2 Characteristics of the 70 patients included in the study

| Variables | ZZ (n = 32) | Z- (n = 29) | Other (n = 9) | p value |
|-----------------------------------|-------------|-------------|---------------|---------|
| Age, years | 54.6 (15.4) | 50.1 (13.5) | 47 (17.6) | 0.235 |
| Sex, male (%) | 20 (62.5) | 16 (55.2) | 3 (33.3) | 0.297 |
| BMI (kg/m ²) | 24.1 (3.2) | 24.7 (3.5) | 24.6 (4.2) | 0.683 |
| Smokers (%) | 0 | 6 (20.7) | 1 (11.1) | 0.120 |
| Ex-smokers (%) | 18 (58.1) | 14 (48.3) | 4 (44.4) | |
| Never smokers (%) | 13 (41.9) | 9 (31) | 4 (44.4) | |
| Tobacco exposure (pack-years) | 22.7 (14.6) | 32.4 (34.1) | 34 (16.7) | 0.360 |
| COPD (%) | 21 (65.6) | 9 (31) | 2 (22) | 0.008 |
| Charlson index | 2.2 (1.6) | 1.5 (1.3) | 1.5 (1.9) | 0.122 |
| FVC (%) | 83 (27) | 100 (19) | 104 (15) | 0.014 |
| FEV ₁ (%) | 69 (32) | 92 (31.3) | 99 (15) | 0.007 |
| FEV ₁ /FVC | 63 (16) | 71 (17) | 76 (4.8) | 0.028 |
| LSM (kPa) | 5.3 (1.2) | 4.5 (1.2) | 4.4 (0.9) | 0.008 |
| FIB-4 | 1.5 (0.9) | 1.1 (0.4) | 1.1 (0.6) | 0.115 |
| Augmentation therapy (%) | 11 (34) | 0 | 0 | <0.001 |
| Haemoglobin (g/dL) | 15.4 (1.4) | 14.4 (1.2) | 14.2 (1.2) | 0.008 |
| Leukocytes (× 10 ⁹ /L) | 7.6 (2.7) | 7.6(2.8) | 7.1 (1.5) | 0.922 |
| Platelets (× 10 ⁹ /L) | 242 (71) | 245 (54) | 282 (51) | 0.163 |
| AST (IU/L) | 29.9 (12.2) | 24.4 (7.2) | 29.6 (18.9) | 0.129 |
| ALT (IU/L) | 30.4 (18.1) | 25.8 (14.1) | 24.9 (13.7) | 0.392 |
| ALP (IU/L) | 81.6 (25.2) | 78.6 (29.2) | 80.5 (21.5) | 0.819 |
| GGT (U/L) | 32.9 (16.1) | 37.5 (51.5) | 41.8 (18.8) | 0.234 |
| Proteins (g/dL) | 7.1 (0.5) | 7.3 (0.3) | 7.2 (0.5) | 0.489 |
| AAT (mg/dL) | 40 (36) | 74 (25) | 82 (22) | <0.001 |
| CRP (mg/L) | 0.2 (0.2) | 0.3 (0.6) | 0.2 (0.2) | 0.261 |
| Fibrinogen (g/L) | 3.7 (0.5) | 3.8 (0.8) | 3.9 (0.7) | 0.353 |
| ELF | 8.7 (0.9) | 8.1 (0.7) | 8.6 (0.8) | 0.004 |
| AAT polymers (µg/mL) | 37.4 (16.4) | 13.5 (8) | 2.3 (2.9) | <0.001 |
| AAT polymers, % | 12.8 (7.2) | 2.2 (2) | 0.3 (0.5) | <0.001 |

Values are mean (standard deviation) unless otherwise specified. *Patient group* ZZ: homozygous patients to the Z allele; -Z: heterozygous patients to the Z allele (Pi*MZ, Pi*SZ, Pi*MMaltonZ, Pi*PlowelZ, Pi*FZ); other: Pi*SS, Pi*SI, Pi*MMattawa, Pi*MMalton, Pi*SMalton and Pi*MMvall d'hebron)

BMI body mass index, *COPD* Chronic obstructive pulmonary disease, *FVC* forced vital capacity, *FEV₁* forced expiratory volume in the first second, *FIB-4* fibrosis-4 score, *LSM* liver stiffness measurement, *FIB-4* fibrosis-4 score, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *ALP* alkaline phosphatase, *GGT* gamma-glutamyl transferase, *AAT* alpha-1 antitrypsin, *CRP* C-reactive protein, *ELF* enhanced liver fibrosis test

Considering the different genotypes individually, the highest values were observed in augmented Pi*ZZ patients (42.9 µg/mL (SD = 16) and one Pi*FZ with 42.1 µg/mL, very close to the 34.5 µg/mL (SD = 16.2) obtained in untreated Pi*ZZ patients. The lowest values were observed in controls (1.04 µg/mL (SD = 1.73) for Pi*MM and 0.9 µg/mL (SD = 1.7) for Pi*MS) and in patients with the Pi*SS and Pi*SI genotypes. Patients heterozygous for the Z allele and other rare variants had intermediate values (Table 3 and Fig. 1). The distribution of CP in percentage followed a similar distribution among genotypes (Table 3).

Correlation between circulating polymers and parameters of lung and liver impairment in untreated Pi*ZZ and Z-heterozygous patients


In order to determine the possible relationship between CP concentrations and lung and liver alterations, we selected homozygous or heterozygous patients carrying the Z allele, excluding those on augmentation therapy. A negative, significant and weak linear relationship was found between CP concentrations and parameters of airflow obstruction; FEV₁/FVC $r = -0.32$, $p = 0.026$ and FEV₁ (%) $r = -0.31$, $p = 0.029$ (Fig. 2). Similarly, a positive and weak linear relationship was found between CP and LSM and ELF ($r = 0.39$ $p = 0.005$ and $r = 0.38$ $p = 0.007$, respectively) (Fig. 3). In contrast,

Table 3 Circulating polymer concentrations of the different AATD genotypes


| AATD genotype | AAT polymers (µg/mL) | AAT polymers (%) | AAT (mg/dL) |
|----------------------------|----------------------|------------------|--------------|
| Patients (n = 70) | | | |
| Pi*ZZ treated (n = 11) | 42.9 (16) | 9.2 (9.6) | 73.5 (46.9) |
| Pi*FZ (n = 1) | 42.1 (-) | 6.2 (-) | 67.7 (-) |
| Pi*ZZ untreated (n = 21) | 34.5 (16.2) | 14.7 (4.8) | 23.1 (5.9) |
| Pi*MmaltonZ (n = 1) | 22.8 (-) | 10.2 (-) | 22.2 (-) |
| Pi*PlowellZ (n = 1) | 15.8 (-) | 4.5 (-) | 35.3 (-) |
| Pi*SZ (n = 13) | 14.2 (4.2) | 2.39 (0.6) | 58.8 (8.3) |
| Pi*MZ (n = 13) | 9.78 (6.3) | 0.98 (0.5) | 97 (16.5) |
| Pi*SMmalton (n = 1) | 6.9 (-) | 1.45 (-) | 47.9 (-) |
| Pi*MMmattawa (n = 1) | 5.5 (-) | 0.8 (-) | 66.9 (-) |
| Pi*MMvall d'hebron (n = 1) | 4.1 (-) | 0.3 (-) | 126 (-) |
| Pi*MMmalton (n = 2) | 2.3 (3.2) | 0.2 (0.3) | 80.7 (18.5) |
| Pi*SS (n = 3) | 0 | 0 | 84.1 (10.5) |
| Pi*SI (n = 1) | 0 | 0 | 85.0 (-) |
| Controls (n = 47) | | | |
| Pi*MM (n = 35) | 1.04 (1.73) | 0.06 (0.1) | 172.7 (34.3) |
| Pi*MS (n = 12) | 0.9 (1.7) | 0.06 (0.1) | 142.7 (20.1) |

Values are mean (standard deviation)

AATD alpha-1 antitrypsin deficiency, AAT alpha-1 antitrypsin



correlations between AAT serum levels and lung and liver parameters were not significant (data not shown).




Circulating polymer concentrations in patients according to the combined presence of lung and liver disease

The same group of unaugmented patients with one or two Z alleles was divided into four subgroups according to lung and liver impairment, using the cut-off of FEV₁/FVC < 0.7 as diagnostic of COPD and LSM ≥ 6 kPa cut-off as suggestive of mild liver fibrosis. One patient was excluded from analysis due to missing data of LSM.

There was a gradient of CP concentrations, with the highest concentration in two patients with both lung and liver impairment (mean = 47.5 µg/mL), followed by six patients with liver abnormality only (mean CP = 34 µg/mL) and 18 with lung impairment only (mean CP = 26.5 µg/mL). Those with no abnormalities had the lowest CP concentrations (Table 4). Differences in CP concentrations between the four groups were significant (p = 0.004).

The possible confounding effect of smoking was analysed, but there were only six current smokers among the 49 subjects (12.2%), being evenly distributed among the groups. Therefore, a possible confounding effect of smoking in our results can be reasonably ruled out.



Discussion

Our results show that overall Pi*ZZ patients presented the highest levels of CP of AAT, followed by heterozygous Z patients and individuals with rare variants. The lowest CP concentrations were observed in controls with Pi*MM and Pi*MS genotypes and patients carrying the S allele, with undetectable levels in the few Pi*SS patients analysed. CP concentrations were significantly higher in patients with both lung and liver disease and correlated with the degree of alteration in lung function and liver stiffness.

Alpha-1 antitrypsin polymers are aggregates of misfolded protein and are deposited within the ER of hepatocytes, which is the basis of the pathogenesis of liver disease in AATD [7, 21]. Although most of the polymers remain as inclusion bodies in the ER of hepatocytes, some are secreted into the blood stream [13, 14]. Polymers are also secreted by alveolar macrophages and have a pro-inflammatory and chemotactic role for inflammatory cells in the lung. The polymers within alveolar macrophages have no anti-elastase activity, thereby contributing to a greater imbalance of the protease-antiprotease axis [22, 23]. Moreover, studies

have shown that, apart from inactivating AAT by oxidation, cigarette smoke also increases the concentration of AAT polymers within alveolar macrophages [12, 24].

In our study, Z homozygous patients presented the highest concentrations of CP followed by Z heterozygous patients. These data were previously observed by Tan et al. [13], who reported the highest concentrations of CP in Pi*ZZ patients, a low signal in normal Pi*MM individuals and remained undetected in S-homozygous individuals. Other studies have also reported that, among the most frequent variants, the Z mutation polymerises the most and the S the least [21, 25, 26].

Patients with the Pi*ZZ genotype on augmentation therapy presented higher CP levels than untreated patients, despite blood samples being taken just before the following dose of augmentation therapy when plasma levels of exogenous AAT are minimal. This observation confirms previous studies that demonstrate the presence of AAT polymers in the augmentation therapy preparations [27] having a direct correlation with serum levels of AAT [28]. To avoid possible confounding effects caused by augmentation therapy, augmented patients were excluded from further analysis.

In order to assess the relationship between CP and variables of liver and lung disease we used data from untreated homozygous or heterozygous carriers of the Z allele. We found a negative relationship between CP concentrations and airflow obstruction parameters and a significant and positive linear relationship with LSM and ELF, suggesting that higher concentrations of CP are related to lung and liver damage. These findings are in agreement with a previous study on 244 Pi*ZZ individuals, that found a negative linear relationship between CP concentrations and the FEV₁/FVC ratio. Moreover, although that study was not designed to assess liver disease, patients who self-reported abnormal liver function, liver disease or cirrhosis had higher CP concentrations than those without a history of liver involvement [13]. In a biopsy study, Mela et al. [29] found that higher polymer loads within hepatocytes were related to senescence of the cells and liver fibrosis. However, to the best of our knowledge, no other studies have related CP concentrations with LSM or ELF and this is important since transient elastography is increasingly used for the screening and follow-up of liver disease in patients with AATD [30, 31], and ELF is a systemic biomarker of liver fibrosis [18]. The importance of the polymerisation of mutated AAT in the pathogenesis of liver and lung disease in AATD has stimulated the development of new strategies of treatment for AATD based on the blockade of polymer formation [32, 33].

Our study has some limitations: (1) the cross-sectional design does not allow to establish a causal

Table 4 Polymer concentrations and clinical characteristics: liver and/or lung disease

| Patients heterozygous for the Z allele and untreated patients with the Pi*ZZ genotype (n = 49) | | | | |
|--|-------------------------------------|----------------------------------|------------------------------------|---------------------------------|
| | No COPD and LSM < 6 kPa (n = 23) | COPD and LSM < 6 kPa (n = 18) | No COPD and LSM ≥ 6 kPa (n = 6) | COPD and LSM ≥ 6 kPa (n = 2) |
| AAT (mg/dL) | 61.1 (33.2) | 39.4 (22.8) | 47.5 (38.3) | 76.1 (56.4) |
| AAT polymers (µg/mL) | 14.4 (8) | 26.5 (14.4) | 34.0 (21.6) | 47.5 (32.8) |
| AAT polymers (%) | 4.7 (5.4) | 9.8 (7.5) | 11.2 (7.9) | 10.8 (12.2) |
| Untreated patients with Pi*ZZ genotype (n = 21) | | | | |
| | No COPD and LSM < 6 kPa (n = 6) | COPD and LSM < 6 kPa (n = 10) | No COPD and LSM ≥ 6 kPa (n = 4) | COPD and LSM ≥ 6 kPa (n = 1) |
| AAT (mg/dL) | 19.4 (3.8) | 22.4 (3.6) | 27.4 (7.6) | 36 (–) |
| AAT polymers (µg/mL) | 25.3 (2.9) | 32.3 (14.9) | 44.7 (17.8) | 70.3 (–) |
| AAT polymers (%) | 13.2 (1.6) | 14.5 (6.5) | 16 (3.3) | 19.4 (–) |

COPD is defined as FEV₁/FVC < 0.7

LSM liver stiffness measurement, AAT alpha-1 antitrypsin

relationship between CP and liver and lung disease, and thus, longitudinal studies are necessary; (2) to demonstrate the impact of the load of CP on clinically relevant liver disease, a cut-off of LSM ≥ 6 kPa was used as suggestive of mild liver fibrosis. Although there is no validated cut-off of LSM for liver disease in AATD, we chose an arbitrary cut-off of LSM ≥ 6 kPa to be as sensitive as possible to detect cases of liver impairment [34–36]. (3) Finally, since AATD is a rare disease, we could not include enough patients with genotypes other than Z. Therefore, larger studies are required to demonstrate the importance of CP in the pathogenesis of lung and liver disease in rare variants. Data from large registries may help to identify patients with rare AATD variants [37, 38].

Conclusions

Our results show that Pi*ZZ and heterozygous Z individuals present higher levels of CP than other AAT genotypes, and CP were associated with the presence and severity of lung and liver disease. Therefore, CP concentrations may help to identify AATD patients at greater risk of developing lung and liver disease and may provide some insight into the mechanisms of the disease. Larger studies are needed to demonstrate the importance of CP in other rare genotypes.

Abbreviations

AAT: Alpha-1 antitrypsin; AATD: Alpha-1 antitrypsin deficiency; ALAT: Alanine-aminotransferase; ANOVA: One-way analysis of variance; ASAT: Aspartate-aminotransferase; COPD: Chronic obstructive pulmonary disease; CP: Circulating polymers; CRP: C-reactive protein; ELF: Enhanced liver fibrosis; ELISA: Enzyme-Linked immunosorbent assay; ER: Endoplasmic reticulum;

FEV₁: Forced expiratory volume in one second; FIB-4: Fibrosis-4; FVC: Forced vital capacity; kPa: Kilopascals; LSM: Liver stiffness measurement; mAb: Monoclonal antibody; Pi*: Protease inhibitor; SD: Standard deviation; TMB: 3,3',5,5'-Tetramethylbenzidine.

Acknowledgements

Mònica Pons is the recipient of a Rio Hortega contract in the 2018 Strategic Action Health Call from the Instituto de Salud Carlos III for the years 2019–2020. Alexa Núñez is the recipient of a Rio Hortega contract in the 2019 Strategic Action Health Call from the Instituto de Salud Carlos III for the years 2020–2022.

Authors' contributions

The study concept and design: AN, IB, MB, FR-F, MM, CE. The acquisition of the data: AN, IB, EM, MB, GF, EL, MP, ER. Analysis or interpretation of the data: CE, AN, IB, FR-F, JG, PG-M, MM. The statistical analysis: CE. The drafting of the manuscript: AN, MM. Critical revision and approval for submission: IB, EM, MB, GF, EL, MP, FR-F, PG-M, ER, JG, CE. All authors read and approved the final manuscript.

Funding

This study was supported by funding from Grifols to the Catalan Center for Research in Alpha-1 antitrypsin deficiency of the Vall d'Hebron Research Institute (VHIR) in the Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain and with a grant from the Fundació Catalana de Pneumologia (FUCAP).

Availability of data and materials

Data are available from the authors under request.

Declarations

Ethics approval and consent to participate

The study was carried out according to the principles of the Declaration of Helsinki and the prevailing norms for performing investigation in humans. Data confidentiality was ensured according to the Law of Data Protection 2016/679. The study was approved by the Ethical Committee and Clinical Investigation of the Vall d'Hebron University Hospital (Barcelona, Spain) number PR (AG) 156/2016, and all the participants provided written informed consent.

Consent for publication

Not applicable.

Competing interests

Cristina Esquinas has received speaker fees from CSL Behring. Marc Miravittles has received speaker or consulting fees from AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Laboratorios Esteve, Gebro Pharma, Kamada, GlaxoSmithKline, Grifols, Johnson & Johnson, Menarini, Mereo Biopharma, Novartis, pH Pharma, Palobiofarma SL, Rovi, TEVA, Spin Therapeutics, Verona Pharma and Zambon, and research grants from Grifols. Miriam Barrecheguren has received speaker fees from Grifols, Menarini, CSL Behring, GSK and consulting fees from GSK, Novartis, Boehringer Ingelheim and Gebro Pharma. Esther Rodríguez has received speaker fees from CSL Behring, TEVA and GlaxoSmithKline. The remaining authors report no conflicts of interest.

Author details

¹Pneumology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, P. Vall d'Hebron 119-129, 08035 Barcelona, Spain. ²Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain. ³Department of Biology and Biotechnologies, 'Charles Darwin' and Pasteur Institute - Cenci Bolognietti Foundation, Sapienza University of Rome, Rome, Italy. ⁴Pneumology Department, Teknon Medical Center, Barcelona, Spain. ⁵Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. ⁶Department of Clinical Biochemistry, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. ⁷Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, (CIBEREHD), Barcelona, Spain. ⁸Clinical Biochemistry Research Group/Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. ⁹Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.

Received: 2 July 2021 Accepted: 8 September 2021

Published online: 15 September 2021

References

- Casas F, Blanco I, Martínez MT, Bustamante A, Miravittles M, Cadenas S, et al. Indications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic pulmonary obstructive disease: an update. *Arch Bronconeumol*. 2015;51(4):185–92.
- Luisetti M, Seersholm N. Alpha- antitrypsin deficiency epidemiology of alpha-1 antitrypsin deficiency. *Thorax*. 2004;59(2):164–9.
- Stoller JK, Aboussouan LS. A review of α 1-antitrypsin deficiency. *Am J Respir Crit Care Med*. 2012;185:246–59.
- Stoller JK, Brantly M. The challenge of detecting alpha-1 antitrypsin deficiency. *COPD*. 2013;10(1):26–34.
- Blanco I, Bueno P, Diego I, Pérez-Holanda S, Casas F, Esquinas C, et al. Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update. *Int J Chron Obstruct Pulmon Dis*. 2017;12:561–9.
- Blanco I, Bueno P, Diego I, Pérez-Holanda S, Lara B, Casas-Maldonado F, et al. Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide. *Int J Chron Obstruct Pulmon Dis*. 2017;12:1683–94.
- Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha-1-antitrypsin deficiency. *N Engl J Med*. 1986;314:736–9.
- Strnad P, McElvaney NG, Lomas DA. Alpha-1-antitrypsin deficiency. *N Engl J Med*. 2020;382(15):1443–55.
- Janciauskiene S, DeLuca DS, Barrecheguren M, Welte T, Miravittles M. Serum levels of Alpha-1-antitrypsin and their relationship with COPD in the general Spanish population. *Arch Bronconeumol*. 2020;56:76–83.
- Ellis P, Turner A. What do alpha-1 antitrypsin levels tell us about chronic inflammation in COPD? *Arch Bronconeumol*. 2020;56:72–3.
- Elliott PR, Bilton D, Lomas DA. Lung polymers in Z alpha-1-antitrypsin deficiency-related emphysema. *Am J Respir Cell Mol Biol*. 1998;18:670–4.
- Alam S, Li Z, Janciauskiene S, Mahadeva R. Oxidation of Z α 1-antitrypsin by cigarette smoke induces polymerization: a novel mechanism of early-onset emphysema. *Am J Respir Cell Mol Biol*. 2011;45:261–9.
- Tan L, Dickens JA, Demeo DL, Miranda E, Perez J, Rashid ST, et al. Circulating polymers in α 1-antitrypsin deficiency. *Eur Respir J*. 2014;43:1501–4.
- Fra A, Cosmi F, Ordoñez A, Berardelli R, Perez J, Guadagno NA, et al. Polymers of Z α 1-antitrypsin are secreted in cell models of disease. *Eur Respir J*. 2016;47(3):1005–9.
- Miravittles M, Herr C, Ferrarotti I, Jordi R, Rodríguez-Frías F, Luisetti M, et al. Laboratory testing of individuals with severe AAT deficiency in three European centres. *Eur Respir J*. 2010;35:960–8.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373–83.
- EASL-ALEH Clinical Practice Guidelines. Non-invasive tests for evaluation of liver disease severity and prognosis. *J Hepatol*. 2015;63(1):237–64.
- Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. *J Hepatol*. 2013;59(2):236–42.
- Miravittles M, Dirksen A, Ferrarotti I, Kobliczek V, Lange P, Mahadeva R, et al. European Respiratory Society Statement: diagnosis and treatment of pulmonary disease in alpha-1 antitrypsin deficiency. *Eur Respir J*. 2017;50:1700610.
- Miranda E, Pérez J, Ekeowa UI, Hadzic N, Kalsheker N, Gooptu B, et al. A novel monoclonal antibody to characterize pathogenic polymers in liver disease associated with alpha-1-antitrypsin deficiency. *Hepatology*. 2010;52(3):1078–88.
- Laffranchi M, Elliston EL, Miranda E, Perez J, Ronzoni R, Jagger AM, et al. Intrahepatic heteropolymerization of M and Z alpha-1-antitrypsin. *JCI Insight*. 2020;5(14):e135459.
- Mulgrew AT, Taggart CC, Lawless MW, Greene CM, Brantly ML, O'Neill SJ, et al. Z alpha-1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. *Chest*. 2004;125:1952–7.
- Mahadeva R, Atkinson C, Li Z, Stewart S, Janciauskiene S, Kelley DG, et al. Polymers of Z alpha-1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. *Am J Pathol*. 2005;166:377–86.
- Bazzan E, Tinè M, Biondini D, Benetti R, Baraldo S, Turato G, et al. α -antitrypsin polymerizes in alveolar macrophages of smokers with and without α -antitrypsin deficiency. *Chest*. 2018;154(3):607–16.
- Gooptu B, Lomas DA. Polymers and inflammation: disease mechanisms of the serpinopathies. *J Exp Med*. 2008;205(7):1529–34.
- Ekeowa UI, Marciniak SJ, Lomas DA. Alpha-1- antitrypsin deficiency and inflammation. *Expert Rev Clin Immunol*. 2011;7(2):243–52.
- Boerema DJ, An B, Gandhi RP, Papineau R, Regnier E, Wilder A, et al. Biochemical comparison of four commercially available human α -proteinase inhibitors for treatment of α -antitrypsin deficiency. *Biologics*. 2017;50:63–72.
- Schmid ST, Koepke J, Dresel M, Hattesoehl A, Frenzel E, Perez J, et al. The effects of weekly augmentation therapy in patients with PiZZ α 1-antitrypsin deficiency. *Int J Chron Obstruct Pulmon Dis*. 2012;7:687–96.
- Mela M, Smeeton W, Davies SE, Miranda E, Scarpini C, Coleman N, et al. The alpha-1 antitrypsin polymer load correlates with hepatocyte senescence, fibrosis stage and liver-related mortality. *Chronic Obstr Pulm Dis*. 2020;7(3):151–62.
- Pons M, Núñez A, Esquinas C, Torres-Durán M, Rodríguez-Hermosa JL, Calle M, et al. Utility of transient elastography for the screening of liver disease in patients with alpha-1-antitrypsin deficiency. *J Clin Med*. 2021;10(8):1724.
- Guillaud O, Dumortier J, Traclot J, Restier L, Joly P, Chapuis-Cellier C, et al. Assessment of liver fibrosis by transient elastography (Fibroscan®) in patients with A1AT deficiency. *Clin Res Hepatol Gastroenterol*. 2019;43(1):77–81.
- Ordóñez A, Pérez J, Tan L, Dickens JA, Motamedi-Shad N, Irving JA, et al. A single-chain variable fragment intrabody prevents intracellular polymerization of Z α 1-antitrypsin while allowing its antiproteinase activity. *FASEB J*. 2015;29(6):2667–78.
- Lomas DA, Irving JA, Arico-Muendel C, Belyanskaya S, Brewster A, Brown M, et al. Development of a small molecule that corrects misfolding and increases secretion of Z α -antitrypsin. *EMBO Mol Med*. 2021;13(3):e13167.
- Colombo S, Belloli L, Zaccanelli M, Badia E, Jamoletti C, Buonocore M, et al. Normal liver stiffness and its determinants in healthy blood donors. *Dig Liver Dis*. 2011;43:231–6.

35. Kim SU, Choi GH, Han WK, Kim BK, Park JY, Kim DY, et al. What are 'true normal' liver stiffness values using FibroScan?: a prospective study in healthy living liver and kidney donors in South Korea. *Liver Int.* 2010;30:268–74.
36. Roulot D, Czernichow S, Le Clesiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. *J Hepatol.* 2008;48:606–13.
37. Barrecheguren M, Torres-Duran M, Casas-Maldonado F, Miravittles M. Spanish implementation of the new international alpha-1 antitrypsin deficiency international registry: The European Alpha-1 Research Collaboration (EARCO). *Arch Bronconeumol.* 2021;57(2):81–2.
38. Miravittles M, Nuñez A, Torres-Durán M, Casas-Maldonado F, Rodríguez-Hermosa JL, López-Campos JL, et al. The importance of reference centers and registries for rare diseases: the example of alpha-1 antitrypsin deficiency. *COPD.* 2020;17(4):346–54.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

